{"id":"W2592994249","doi":"10.1158/1538-7445.sabcs16-p4-22-06","title":"Abstract P4-22-06: Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Palbociclib; Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Hazard ratio; Breast cancer; Progression-free survival; Cancer; Oncology; Chemotherapy; Placebo; Gynecology; Tamoxifen; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004624131,0.00034583,0.0008049802,0.000174777,0.0002846832,0.0003464441,0.0003363594,0.0005032734,0.003486637],"category_scores_gemma":[0.0005787828,0.0001659517,0.0007119902,0.0002182158,0.0002885476,0.0003198683,0.0002207745,0.001101048,0.0004672753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004641843,"about_ca_system_score_gemma":0.0007519499,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009211558,"about_ca_topic_score_gemma":0.002830592,"domain_scores_codex":[0.999836,0.00006489641,0.000009816409,0.00002678677,0.0000148399,0.00004768274],"domain_scores_gemma":[0.999678,0.00006252997,0.0000559591,0.00001793074,0.00001635486,0.000169177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7438746,0.02180394,0.07946756,0.0004200485,0.000753506,0.00107159,0.0002053523,0.0008127196,0.01749117,0.00007659199,0.002135902,0.131887],"study_design_scores_gemma":[0.1379471,0.5600159,0.2899401,0.00006353937,0.0009265274,0.001033724,0.0001700029,0.001046974,0.004444253,0.0001535171,0.004226258,0.00003213135],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981018,0.0004534202,0.00005607964,0.000142011,0.00002023609,0.0002432258,0.0003466858,0.00001014468,0.0006264701],"genre_scores_gemma":[0.998033,0.0002161439,0.0001260081,0.0001638088,0.00003796554,0.0002413523,0.0004798273,0.000002463269,0.0006994148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003486637,"threshold_uncertainty_score":0.01166397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05030317000219856,"score_gpt":0.4175466863526979,"score_spread":0.3672435163504993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}